Drug Profile
Autologous cultured chondrocytes - Curis
Alternative Names: ChondrogelLatest Information Update: 20 Feb 2003
Price :
$50
*
At a glance
- Originator Curis
- Class Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stress incontinence; Vesicoureteral reflux
Most Recent Events
- 30 Apr 2002 Discontinued - Phase-II for Stress incontinence in USA (Injection)
- 01 Apr 2002 Discontinued - Phase-III for Vesicoureteral reflux in USA (Injection)
- 28 Mar 2002 Chondrogel™ is available for licensing in the USA (http://www.curis.com/)